Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics

被引:41
作者
Bender, S
Grohmann, R
Engel, RR
Degner, D
Dittmann-Balcar, A
Rüther, E
机构
[1] Univ Duisburg Gesamthsch, Dept Psychiat & Psychotherapy, Essen, Germany
[2] Univ Munich, Dept Psychiat, D-8000 Munich, Germany
[3] Univ Gottingen, Dept Psychiat & Psychotherapy, D-3400 Gottingen, Germany
关键词
D O I
10.1055/s-2004-815510
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Numerous studies compare side effects or adverse drug reactions (ADRs) of the various typical and newer atypical neuroleptics in patients with schizophrenia. However, these Studies, as controlled randomized trials, represent an artificial setting of drug administration and do not easily relate to the "real-life" setting of psychiatric treatment. In contrast, the AMSP drug safety program allows the monitoring of ADRs of all types of psychopharmacological agents in the naturalistic setting of routine clinical practice. In the present study, the data on neuroleptics acquired in the AMSP program from 1993 to 2000 are analyzed. In this period, 86,439 patients treated with at least one neuroleptic agent were monitored. In 1.1% of the patients severe ADRs occurred. In contrast to the results from controlled trials, atypical neuroleptics caused more severe ADRs than did typical neuroleptics. This result was mainly caused by the high number of severe ADRs in patients treated with clozapine and concerned delirium and non-EPS neurological, gastrointestinal, hepatic, dermatological, hematological, and endocrinological ADRs. Atypical neuroleptics were found to be superior in EPS and urological ADRs. Excluding the data on clozapine, we found typical and atypical neuroleptics to be similar in the occurrence of severe ADRs, although the profiles differ between these two groups as well as between the single substances. Our findings provide valuable information on the type and frequency of ADRs in psychiatric practice, thus enabling differential indication of neuroleptics based not only on the efficacy and tolerability data of controlled trials but also on their differential ADR profile Occurring in the "real-life" setting of routine clinical treatment.
引用
收藏
页码:S46 / S53
页数:8
相关论文
共 26 条
[1]   Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics [J].
Barnes, TRE ;
McPhillips, MA .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :34-43
[2]   Antipsychotic efficacy of the antidepressant trimipramine: A randomized, double-blind comparison with the phenothiazine perazine [J].
Bender, S ;
Olbrich, HM ;
Fischer, W ;
Hornstein, C ;
Schoene, W ;
Falkai, P ;
Haarmann, C ;
Berger, M ;
Gastpar, M .
PHARMACOPSYCHIATRY, 2003, 36 (02) :61-69
[3]   Asymptomatic pancreatitis associated with clozapine [J].
Bergemann, N ;
Ehrig, C ;
Diebold, K ;
Mundt, C ;
von Einsiedel, R .
PHARMACOPSYCHIATRY, 1999, 32 (02) :78-80
[4]  
Caroff SN, 2002, J CLIN PSYCHIAT, V63, P12
[5]  
Conley RR, 2000, J CLIN PSYCHIAT, V61, P26
[6]   Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [J].
Geddes, J ;
Freemantle, N ;
Harrison, P ;
Bebbington, P .
BRITISH MEDICAL JOURNAL, 2000, 321 (7273) :1371-1376
[7]   Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program:: Methods and first results for tricyclic antidepressants and SSRI [J].
Grohmann, R ;
Rüther, E ;
Engel, RR ;
Hippius, H .
PHARMACOPSYCHIATRY, 1999, 32 (01) :21-28
[8]   The AMSP drug safety program:: Methods and global results [J].
Grohmann, R ;
Engel, RR ;
Rüther, E ;
Hippius, H .
PHARMACOPSYCHIATRY, 2004, 37 :S4-S11
[9]   The AMUP study for drug surveillance in psychiatry -: a summary of inpatient data [J].
Grohmann, R ;
Hippius, H ;
Helmchen, H ;
Rüther, E ;
Schmidt, LG .
PHARMACOPSYCHIATRY, 2004, 37 :S16-S26
[10]  
GROHMANN R, 1994, UNERWUNSCHTE WIRKUNG